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Accuracy of mobile digital teledermoscopy for skin 
self-examinations in adults at high risk of skin cancer: 
an open-label, randomised controlled trial
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Rainer Hofmann-Wellenhof, Allan Halpern, David C Whiteman, Jennifer A Whitty, B Mark Smithers, H Peter Soyer
Summary
Background Skin self-examinations supplemented with mobile teledermoscopy might improve early detection of skin 
cancers compared with naked-eye skin self-examinations. We aimed to assess whether mobile teledermoscopy-
enhanced skin self-examination can improve sensitivity and specificity of self-detection of skin cancers when 
compared with naked-eye skin self-examination.
Methods This randomised, controlled trial was done in Brisbane (QLD, Australia). Eligible participants (aged ≥18 years) 
had at least two skin cancer risk factors as self-reported in the eligibility survey and had to own or have access to an 
iPhone compatible with a dermatoscope attachment (iPhone versions 5–8). Participants were randomly assigned (1:1), 
via a computer-generated randomisation procedure, to the intervention group (mobile dermoscopy-enhanced self-skin 
examination) or the control group (naked-eye skin self-examination). Control group and intervention group participants 
received web-based instructions on how to complete a whole body skin self-examination. All participants completed 
skin examinations at baseline, 1 month, and 2 months; intervention group participants submitted photographs of 
suspicious lesions to a dermatologist for telediagnosis after each skin examination and control group participants 
noted lesions on a body chart that was sent to the research team after each skin examination. All participants had an 
in-person whole-body clinical skin examination within 3 months of their last skin self-examination. Primary outcomes 
were sensitivity and specificity of skin self-examination, patient selection of clinically atypical lesions suspicious for 
melanoma or keratinocyte skin cancers (body sites examined, number of lesions photographed, types of lesions, and 
lesions missed), and diagnostic concordance of telediagnosis versus in-person whole-body clinical skin examination 
diagnosis. All primary outcomes were analysed in the modified intention-to-treat population, which included all 
patients who had a clinical skin examination within 3 months of their last skin self-examination. This trial was 
registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12616000989448.
Findings Between March 6, 2017, and June 7, 2018, 234 participants consented to enrol in the study, of whom 116 (50%) 
were assigned to the intervention group and 118 (50%) were assigned to the control group. 199 participants 
(98 participants in the intervention group and 101 participants in the control group) attended the clinical skin 
examination and thus were eligible for analyses. Participants in the intervention group submitted 615 lesions 
(median 6·0 per person; range 1–24) for telediagnosis and participants in the control group identified and recorded 
673 lesions (median 6·0 per person; range 1–16). At the lesion level, sensitivity for lesions clinically suspicious for skin 
cancer was 75% (95% CI 63–84) in the intervention group and 88% (95% CI 80–91) in the control group (p=0·04). 
Specificity was 87% (95% CI 85–90) in the intervention group and 89% (95% CI 87–91) in the control group (p=0·42). 
At the individual level, the intervention group had a sensitivity of 87% (95% CI 76–99) compared with 97% (95% CI 
91–100) in the control group (p=0·26), and a specificity of 95% (95% CI 90–100) compared with 96% (95% CI 91–100) 
in the control group. The overall diagnostic concordance between the telediagnosis and in-person clinical skin 
examination was 88%.
Interpretation The use of mobile teledermoscopy did not increase sensitivity for the detection of skin cancers 
compared with naked-eye skin self-examination; thus, further evidence is necessary for inclusion of skin 
self-examination technology for public health benefit.
Funding National Health and Medical Research Council (Australia).
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
In the UK, which has a population of 66 million people, 
an estimated 15 970 adults developed melanoma between 
2014 and 2016,1 and 2285 died from the disease in 2016.2 A 
similar number of melanoma cases and deaths associated 
with the disease are observed in Australia3 despite the 
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country having a smaller population than the UK (around 
25 million). The term skin cancer includes melanoma 
(a skin malignancy that stems from the melanocytes), 
keratinocyte cancers (basal cell carcinoma or squamous 
cell carcinoma), which are the most common types of skin 
cancer with more than 210 000 cases reported in 2015 in 
the UK,4 and other less common types of skin cancer. In 
Australia, keratinocyte cancers are more common than 
any other cancer and it is estimated that more than 
560 people die from these cancers each year.5 Diagnosis of 
skin cancers at an earlier stage is strongly associated with 
better survival, lower morbidity, and reduced health-care 
costs.6–8 Since health services are increasingly provided 
digitally using direct-to-consumer technologies,9 further 
evidence is urgently needed to ascertain whether digital 
approaches can optimise early detection of skin cancer, 
especially in populations at high risk.
Most skin cancers, including melanoma, are initially 
detected by patients themselves or by their families.10,11 In 
the absence of population-based screening programmes, 
cancer agencies recommend the practice of regular naked-
eye skin self-examinations, whereby a person checks 
their own skin and consults a doctor if they notice any 
changes.12,13 Previous studies that investigated the sensi-
tivity of skin self-examination found that sensitivity varied 
widely from 25% to 93%;14,15 had small sample sizes; used 
non-randomised trial designs; or asked participants to 
identify skin lesions that had been changed artificially.15
In the past decade, mobile tele dermoscopy technologies 
have become available, offering the potential to improve 
skin self-examination. Mobile teledermoscopy-enhanced 
skin self-examination combines the photographic and 
telecommunication features of smartphones with a 
magnifying device that has a polarised light source. In 
combination with an app, this technology allows people to 
view, photograph, store, and send dermo scopic images of 
suspicious skin lesions to a medical provider. Theoretical 
advantages of mobile teledermoscopy include promoting a 
thorough skin self-examination and requiring close inspec-
tions of skin lesions for photographing. Previous studies 
have assessed the feasibility of mobile tele dermo scopy, 
showing that people can use the imaging and transmission 
process to detect suspicious skin lesions.16–20 However, 
none of these studies directly compared naked-eye skin 
self-examination with mobile teledermoscopy-enhanced 
skin self-exami nation in a randomised trial setting.
We aimed to assess whether mobile teledermoscopy-
enhanced skin self-examination can improve sensitivity 
and specificity of self-detection of skin cancers when 
compared with naked-eye skin self-examination.
Methods
Study design and participants
This open-label, randomised controlled trial was done at 
The University of Queensland and The Queensland 
University of Technology (Brisbane, QLD, Australia). 
Participants were recruited through university email 
channels, television news, and social media. Eligible 
participants were aged 18 years or older; had at least two 
skin cancer risk factors as self-reported in the eligibility 
survey (light skin complexion and fair hair; skin that never 
or rarely tans, and always or mostly burns; a family history 
of melanoma or a personal history of skin cancer, or many 
naevi; and residing in Queensland). Eligible individuals 
also had to have access to an iPhone compatible with the 
dermatoscope attachment (iPhone versions 5–8); had to 
be willing to travel to The Queensland University of 
Technology for an in-person whole-body clinical skin 
examination; and had to have a partner to assess difficult-
to-see body areas. Participants were excluded if they had a 
Research in context
Evidence before this study
Naked-eye skin self-examination is recommended by many 
cancer agencies for the early detection of skin cancers. The use of 
dermoscopy has improved the sensitivity of dermatologists for 
diagnosing skin cancers, but it is unclear whether the use of 
dermoscopy during skin self-examination could also improve the 
sensitivity of lay people when assessing their own skin. 
We searched PubMed for studies published between database 
inception and Sept 30, 2019, using the search terms “mobile 
teledermatology OR mobile teledermoscopy” AND “skin cancer 
OR melanoma”. No previous randomised controlled trials were 
identified that directly compared naked-eye skin self-examination 
(as currently recommended by cancer agencies) with mobile 
teledermoscopy-enhanced skin self-examination.
Added value of this study 
This is the first randomised trial to directly compare mobile 
teledermoscopy assisted skin self-examination with naked-eye 
skin self-examination to assess whether teledermoscopy 
improves the sensitivity and specificity of lay people for selecting 
lesions suspicious for skin cancer. Although previous studies 
have provided evidence for feasibility and acceptability of mobile 
teledermoscopy, accuracy outcomes were not directly compared 
with current best practice guidelines of naked-eye skin self-
examination.
Implications of all the available evidence
In our study, the intervention and control groups achieved high 
sensitivity and similar specificity for the identification of lesions 
suspicious for skin cancer, but supplementing skin examination 
with mobile teledermoscopy did not improve sensitivity for 
skin cancer compared with naked-eye skin self-examination. 
For the early detection of skin cancer, naked-eye skin self-
examination should continue to be recommended by cancer 
agencies.
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history of melanoma within the past 5 years because such 
diagnoses would require frequent surveillance by a doctor.
The study was approved by the Queensland University 
of Technology Human Research Ethics Committee. The 
study protocol is provided in the appendix (p 2) and has 
been published previously.21
Randomisation and masking
Participants were randomly assigned (1:1) to the inter-
vention group or control group using a computer-
generated randomisation sequence. Randomisation was 
done by research staff using trial database software 
(REDCap; Vanderbilt University, Nashville, TN, USA). 
REDCap facilitates allocation concealment; therefore 
research staff were masked to the next sequence. 
Participants, research staff, and dermatologists were 
aware of group allocation. Analyses were done by a 
statistician masked to group allocation.
Procedures
Naked-eye skin self-examination is defined as an indi-
vidual examining themselves for early skin cancer without 
use of examination aids with the exception of a mirror or 
help from a partner to inspect areas of the body that are 
difficult to see. Mobile teledermoscopy is defined as a 
store-and-forward system for sending images of skin 
lesions suspicious for skin cancer to a medical practitioner 
for diagnosis. Intervention group participants received the 
FotoFinder handyscope (FotoFinder Systems GmbH, Bad 
Birnbach, Germany; appendix (p 26) by mail and did 
mobile teledermoscopy-enhanced skin self-examination 
in their homes. Participants were provided with web-
based instructions on how to complete a whole-body skin 
self-examination. To guide selection of lesions suspicious 
for melanoma, participants were provided with the 
asymmetry and colour rule and accompanying macro 
images of melanomas.22 For lesions suspicious for other 
skin cancers, participants were provided with example 
macro images of basal cell carcinoma and squamous cell 
carcinoma and a description of their features. Intervention 
group parti cipants addi tionally received examples of 
dermoscopic images of skin cancers. To allow the assess-
ment of change, participants did skin self-examinations 
at 1 month and 2 months; participants were asked to 
rephotograph the same lesions from baseline and any 
new suspicious lesions that might have developed, and 
send all photographed lesions to the study team via the 
FotoFinder handyscope patient app (appendix p 26). A 
dermatologist (HPS) provided a tele diagnosis for every 
submitted lesion. Participants were advised that they 
would receive the telediagnosis results at the in-person 
clinical skin examination, unless immediate action was 
required (ie, suspected melanoma, basal cell carcinoma, 
or squamous cell carcinoma). Participants who submitted 
photographs indicating that treatment or excision was 
required were contacted within 1 week and asked to visit 
their general practitioner promptly with a referral letter.
The first three teledermoscopic images submitted by a 
random sample of 30 participants (90 lesions) were 
diagnosed by two additional dermatologists (CC-L and 
RH-W) in addition to the study dermatologist (HPS). The 
diagnostic agreement between the three dermatologists 
was 99%.
Participants in the control group were asked to do a 
naked-eye skin self-examination at baseline, mark all 
lesions they were concerned about on a body chart, to 
check the same lesions again at 1 month and 2 months, 
and add any newly noted lesions. Control group parti-
cipants received web-based instructions on how to 
complete a whole-body skin self-examination (the same 
instructions as the intervention group): the asymmetry 
and colour rule, and example macro images of melanoma, 
basal cell carcinoma, and squamous cell carcinoma. After 
every skin check, participants emailed a copy of their 
completed body chart to the research team.
See Online for appendix
For more on the FotoFinder 
handyscope patient app see 
https://apps.apple.com/au/app/
handyscope-patient/
id1175303139
Figure: Trial profile
116 allocated to intervention group 
484 people approached research team to participate 
439 sent eligibility survey 
348 completed eligibility survey  
234 enrolled and randomly assigned 
45 ineligible 
18 excluded
5 lost to follow-up
4 insufficient time
1 moved interstate or overseas
2 had technical difficulties
1 not available for clinical skin 
examination
2 did not have an iPhone 
compatible with dermatoscope 
3 unknown reason
17 excluded
7 lost to follow-up
4 insufficient time
2 moved interstate or overseas 
1 no partner to help with skin 
self-examination
1 already presented to a doctor 
2 unknown reason 
118 allocated to control group
98 attended clinical skin examination 
and included in the analysis 
101 attended clinical skin examination 
and included in the analysis
91 did not complete eligibility survey 
114 excluded
43 did not meet inclusion criteria
36 not enrolled
34 lost to follow-up
1 declined to participate
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All participants had an in-person whole-body clinical 
skin examination by a dermatologist (HPS) within 
3 months of their last skin self-examination.
Outcomes
The primary outcomes were sensitivity and specificity of 
mobile teledermoscopy-enhanced skin self-examination 
versus naked-eye skin self-examination, compared with the 
reference standard of whole-body clinical skin examination 
done by a dermatologist; patient selection of lesions sus-
picious for melanoma or keratinocyte skin cancers (body 
sites examined, number of lesions photo graphed, types of 
lesion, and lesions missed); and diagnostic concordance of 
telediagnosis versus in-person whole-body clinical skin 
examination diagnosis, inclu ding histological diagnosis 
for any excised or biopsied lesions. All primary outcomes 
and secondary outcomes were analysed in the modified 
intention-to-treat population, which included all patients 
who had a clinical skin examination within 3 months of 
their last skin self-examination. Secondary outcomes were 
participant satisfaction with services and willingness to 
pay, which will be reported elsewhere.
Statistical analysis
We anticipated a dropout rate of 5% on the basis of our 
previous studies.18,23 Thus, we calculated that a sample 
size of 110 in each group would be required to provide 
80% power (two-tailed) at the 5% significance level to 
detect an improvement in sensitivity of 20% or higher 
per lesion by mobile teledermoscopy-enhanced skin self-
examination in the lesion-level analysis compared with 
naked-eye skin self-examination.24 Such improvement 
was considered to be clinically relevant and within the 
upper range of improvements achieved in previous 
studies investigating skin self-examination aids.14,15
Detailed analysis methods have been published pre-
viously21 and the statistical analysis plan is provided in 
the appendix (p 15). To calculate sensitivity and specificity, 
lesions that were clinically diagnosed skin cancers or 
their precursors only (including mela noma, squamous 
cell carcinoma, Bowen disease or intra epidermal 
carcinoma, basal cell carcinoma, actinic keratosis, or 
lesions already excised or biopsied after telediagnosis) 
were considered positive. Dysplastic or atypical naevi 
were considered benign lesions. We calculated sensitivity 
and specificity both at the lesion level and individual 
level, adjusting for clustering of lesions within 
participants as previously described by Genders and 
colleagues.25 At the lesion level, a skin lesion was counted 
as true positive if the dermatologist deter mined the 
lesion was a skin cancer, requiring treatment, biopsy, or 
excision at clinical skin examination, and negative if it 
did not require such interventions. Any lesion that the 
participant missed that was then found at the clinical 
visit contributed to the false negative count. The number 
of true negative (benign) skin lesions per person was 
calculated on the basis of participants’ self-reported 
response of having none, few, some, or many naevi, and 
validated clinical whole-body counts, as described by 
Morze and colleagues.26 We also did sensitivity analyses 
by mole count (none [1 mole]; few [around 20 moles]; 
Intervention 
(n=98)
Control 
(n=101)
Total 
(n=199)
Age, years 41·8 (11·8; 19–73) 40·5 (12·6; 18–70) 41·1 (12·2; 18–73)
Sex
Women 67 (68%) 74 (73%) 141 (71%)
Men 31 (32%) 27 (27%) 58 (29%)
Level of education
Primary school or leaving certificate 0 2 (2%) 2 (1%)
High school 9 (9%) 12 (12%) 21 (11%)
Trade or technical certificate 16 (16%) 20 (20%) 36 (18%)
University degree or diploma 73 (74%) 67 (66%) 140 (70%)
Relationship status
Married or cohabiting 76 (78%) 66 (65%) 142 (71%)
Divorced or separated 7 (7%) 11 (11%) 18 (9%)
Single, never married, or not living 
together
15 (15%) 24 (24%) 39 (20%)
Previous skin spot, mole, or other spot removed or treated
Yes 60 (61%) 57 (56%) 117 (59%)
No or unsure 38 (39%) 44 (44%) 82 (41%)
First degree relative with a history of melanoma
Yes 43 (44%) 43 (43%) 86 (43%)
No 55 (56%) 58 (57%) 113 (57%)
Natural skin colour
Very fair 34 (35%) 28 (28%) 62 (31%)
Fair 53 (54%) 62 (61%) 115 (58%)
Medium 10 (10%) 10 (10%) 20 (10%)
Olive or brown 1 (1%) 1 (1%) 2 (1%)
Eye colour
Blue, grey, or green-blue 52 (53%) 53 (52%) 105 (53%)
Green or hazel 28 (29%) 27 (27%) 55 (28%)
Brown or black 18 (18%) 21 (21%) 39 (20%)
Completed skin self-examinations
Baseline 98 (100%) 101 (100%) 199 (100%)
1 month 93 (95%) 101 (100%) 194 (97%)
2 month 81 (83%) 96 (95%) 177 (89%)
Attended clinical skin examination 98 (100%) 101 (100%) 199 (100%)
Type of skin check done during study
Whole body 69 (70%) 85 (84%) 154 (77%)
Partial body 9 (9%) 6 (6%) 15 (8%)
Skin spots only 20 (20%) 10 (10%) 30 (15%)
Did you have someone assist with checking your skin?
Yes 70 (71%) 57 (56%) 127 (63·8%)
No 28 (29%) 44 (44%) 72 (36·2%)
Who helped check your skin?
Partner 59/70 (84%) 49/57 (86%) 108/127 (85%)
Family or friend 9/70 (13%) 5/57 (9%) 14/127 (11%)
Child 1/70 (1%) 3/57 (5%) 4/127 (3%)
Data missing 1/70 (1%) 0 1/127 (1%)
Data are mean (SD; range), n (%), or n/N (%). Some percentages do not sum to 100 because of rounding.
Table 1: Self-reported participant characteristics
Articles
www.thelancet.com/digital-health   Vol 2   March 2020 e133
some [around 30 moles]; and many [≥60 moles]) on the 
basis of the study questionnaire, but the results did not 
change discernibly (data not reported). At the individual 
level, if at least one correct positive skin cancer was 
identified by the participant, a true positive score was 
given even if one or more other skin cancers were 
missed, assuming that these lesions would be identified 
at the clinical skin examination required for the index 
lesion. Statistical analyses were done using R statistical 
software. Functions were written and data were analysed 
using the following methods: χ² tests; adjustment of 
CIs using the ratio estimator; adjustment of CIs using 
the variance inflation factor; generalised estimating 
equations (mean sensitivity and specificity averaged 
across all patients); mixed models (median sensitivity 
and specificity averaged across all patients); and Gwet’s 
agreement coefficient.
This study was prospectively registered with the 
Australian and New Zealand Clinical Trials Registry, 
ACTRN12616000989448.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all of the data and had final responsibility for the decision 
to submit for publication.
Results
Between March 6, 2017, and June 7, 2018, 484 people 
responded to the study call, of whom 348 completed the 
eligibility survey, and 234 were eligible and recruited. Of 
the 234 enrolled participants, 116 (50%) were allocated to 
the intervention group and 118 (50%) to the control group. 
199 (85%) of 234 participants attended the clinical skin 
examination and thus were eligible for analyses (figure).
Among the 199 participants in the analysis population, 
the mean age was 41·1 years (SD 12·2; range 18–73 years), 
141 (71%) were women, 117 (59%) had had a suspected 
skin cancer removed or treated in the past, and 177 (89%) 
had self-reported a very fair or fair skin type. The groups 
were well balanced with regard to baseline characteristics 
(table 1).
Fewer participants in the intervention group completed 
all three skin self-examinations than did participants in 
the control group (81 [83%] of 98 participants vs 96 [95%] 
of 101 participants; χ²=6·56; p=0·01). 69 (70%) of 
98 participants in the intervention group reported doing 
a whole-body skin check compared with 85 (84%) of 
101 participants in the control group (χ²=5·37; p=0·02). 
70 (71%) of 98 participants in the intervention group 
reported they had someone (most commonly a partner) 
assist with checking their skin compared with 57 (56%) 
of 101 participants in the control group (χ²=4·8; p=0·03; 
table 1).
Participants in the intervention group submitted 
615 lesions (median 6·0 per person; range 1–24) once or 
multiple times for telediagnosis and participants in the 
control group marked 673 lesions (median 6·0 per person; 
range 1–16) once or multiple times on the body chart. 
The proportions of lesions that were photographed by 
participants in the intervention group that were deemed 
to require immediate referral by the teledermatologist 
remained stable across all three timepoints (3·5%; 
range 3·3–3·9).
At the clinical skin examination, 1376 lesions were 
assessed by the dermatologist (684 lesions in the inter-
vention group and 692 lesions in the control group), 
including all participant-selected and dermatologist-
selected lesions.
Participants identified 103 suspected skin cancers or 
precursor lesions (50 lesions in the intervention group 
Positive on 
home 
examination 
and CSE, n
Positive on 
home 
examination 
and negative 
on CSE, n
Positive on 
CSE and 
negative on 
home 
examination, 
n
Negative on 
CSE and 
home 
examination, 
n
Concordance Sensitivity 
(95% CI)
p value Specificity 
(95% CI)
p value
Lesion-level analyses
Intervention 50 609 17 4355 88% 75% (63–84) 0·04 87% (85–90) 0·42
Control 53 620 7 5011 89% 88% (80–91) ·· 89% (87–91) ··
Individual-level analyses 
Intervention 28 4 3 63 93% 87% (76–99) 0·26 95% (90–100) 0·96
Control 31 1 3 66 96% 97% (91–100) ·· 96% (91–100) ··
For the lesion-level analyses, data are presented as the number of lesions; for the individual-level analyses, data are presented as number of individuals. Sensitivity and 
specificity calculations included all lesions clinically diagnosed as melanoma, basal cell carcinoma, squamous cell carcinoma, Bowen disease, intraepidermal carcinoma or 
actinic keratosis, and lesions already excised or biopsied after telediagnosis. Concordance was calculated using the following equation: true positives + true negatives/total 
number of lesions (or individuals) × 100. Sensitivity (ie, skin cancer identified during skin self-examination that was also identified by the dermatologist) was calculated using 
the following equation: (true positive screens/true positive plus false negative screens) × 100. Specificity (ie, skin cancer not identified during skin self-examination with 
agreement from the dermatologist) was calculated using the following equation: (true negative screens/true negative screens + false positive screens) × 100. CSE=clinical skin 
examination. 
Table 2: Primary outcomes
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and 53 lesions in the control group) at home that the 
dermatologist deemed to require treatment and missed 
24 skin cancers or precursor lesions that were identified 
by the dermatologist at the clinical skin examination 
(17 lesions in the intervention group and seven lesions in 
the control group). At the lesion level, this resulted in 
sensitivity of 75% (95% CI 63–84) in the intervention 
group and 88% (95% CI 80–91) in the control group 
(p=0·04). Specificity was 87% (95% CI 85–90) in the 
intervention group and 89% (95% CI 87–91) in the 
control group (p=0·42; table 2).
At the individual level, the intervention group had 
a sensitivity of 87% (95% CI 76–99) compared with 
97% (95% CI 91–100) in the control group (p=0·26), 
and a specificity of 95% (95% CI 90–100) compared with 
96% (95% CI 91–100) in the control group (p=0·96; table 2).
At the clinical skin examination, the dermatologist 
identified 44 missed lesions on 36 participants that 
required further monitoring or treatment (25 lesions 
on 18 [18%] of 98 intervention group participants and 
19 lesions on 18 [18%] of 101 control group participants). 
20 (45%) of 44 missed lesions (eight lesions in the 
intervention group and 12 in the control group) did not 
have a primary diagnosis of skin cancer, but required 
referral for monitoring, topical treatments, or cryo-
therapy, and were judged by the dermatologist as 
worthwhile selecting. The proportion of lesions missed 
by participants in difficult-to-see areas such as their back 
was similar between groups (eight [32%] of 25 lesions in 
the intervention group vs six [32%] of 19 lesions in the 
control group; table 3).
In the intervention group, of the 571 lesions identified 
at the 1-month skin self-examination, 32 (6%) lesions 
identified by 19 participants were not rephotographed and 
48 (8%) identified by 29 participants were incorrectly 
photographed by selecting a different lesion than that 
photographed at baseline (table 4). Of the 511 lesions 
identified at the 2-month skin self-examination, 26 lesions 
(5%) identified by 20 participants were not rephotographed, 
and 29 lesions (6%) identified by 18 participants were 
incorrectly photographed by selecting a different lesion 
than that photographed at baseline.
The overall diagnostic concordance between the tele-
diagnosis and in-person clinical skin examination 
diagnosis both done by the same dermatologist (HPS) 
was 88% (Gwet’s agreement coefficient=0·88; 95% CI 
0·87–0·89), indicating substantial agreement.
Seven participants in the intervention group were asked 
to visit their general practitioner for treatment on the 
basis of teledermoscopy findings requiring immediate 
treatment. At clinical skin examination, 59 (30%) parti-
cipants (32 intervention group participants with a total of 
65 lesions; 27 control group participants with a total of 
50 lesions) were asked to visit their doctor for skin lesions 
requiring treatment found either by the participant or the 
study dermatologist. Of these, 41 participants required an 
excision or biopsy for one or more lesions. At the time of 
analysis (April, 2019), 35 (85%) of 41 of these participants 
had visited their doctor and 60 skin lesions were excised 
or biopsied (appendix p 27), of which 44 (73%) of 
60 lesions received the same diagnosis as they received at 
the in-person clinical assessment.
Discussion
Mobile health applications are increasingly used in 
cancer prevention and early detection, but rarely tested 
Lesions missed by participants Primary diagnosis at clinical skin 
examination
Intervention 
(n=18)
Control 
(n=18)
Intervention 
(n=98)
Control 
(n=101)
Total number of lesions 25 19 684 692
Predominantly pigmented lesions
Melanoma* 0 1/19 (5%) 1/684 (<1%) 2/692 (<1%)
Naevus 6/25 (24%) 6/19 (32%) 462/684 (68%) 468/692 (68%)
Lentigo 0 1/19 (5%) 48/684 (7%) 43/692 (6%)
Seborrheic keratosis 0 0 58/684 (8%) 50/692 (7%)
Non-pigmented lesions
Basal cell carcinoma* 11/25 (44%) 4/19 (21%) 17/684 (2%) 16/692 (2%)
Squamous cell carcinoma* 1/25 (4%) 2/19 (11%) 2/684 (<1%) 4/692 (1%)
Actinic keratosis* 5/25 (20%) 0 37/684 (5%) 28/692 (4%)
Angioma 0 0 11/684 (2%) 5/692 (1%)
Other† 2/25 (8%) 5/19 (26%) 33/684 (5%) 46/692 (7%)
Not diagnosed
No lesion found NA NA 5/684 (1%) 15/692 (2%)
Non-specific 0 0 ·· 1/692 (<1%)
Removed before exam NA NA 10/684 (1%) 10/692 (1%)
Data missing 0 0 0 4/692 (1%)
Body area
Back 8/25 (32%) 6/19 (32%) 168/684 (25%) 140/692 (20%)
Arms 7/25 (28%) 3/19 (16%) 132/684 (19%) 118/692 (17%)
Chest or abdomen 4/25 (16%) 2/19 (11%) 111/684 (16%) 98/692 (14%)
Legs 1/25 (4%) 5/19 (26%) 111/684 (16%) 145/692 (21%)
Head and neck 4/25 (16%) 2/19 (11%) 111/684 (16%) 157/692 (23%)
Shoulder 1/25 (4%) 1/19 (5%) 31/684 (5%) 20/692 (3%)
Sensitive areas 0 0 19/684 (3%) 14/692 (2%)
Data missing 0 0 1/684 (<1%) 0
Total number of treatments 
prescribed
25 19 80 93
Excision or shave biopsy 13/25 (52%) 11/19 (58%) 43/80 (54%) 24/93 (26%)
Laser treatment 1/25 (4%) 0 1/80 (1%) 0
Cryotherapy 5/25 (20%) 0 12/80 (15%) 9/93 (10%)
Topical prescription 1/25 (4%) 0 7/80 (9%) 5/93 (5%)
Further monitoring or 
review
3/25 (12%) 8/19 (42%) 7/80 (9%) 44/93 (47%)
Curette or cautery 0 0 0 1/93 (1%)
Removed before exam 2/25 (8%) 0 10/80 (13%) 10/93 (11%)
Data are n or n/N (%). NA=not applicable. *Skin cancers or actinic keratosis only were used for sensitivity and specificity 
calculations as reported in table 4. †Other lesions in the control group included myxoid cyst or ganglion cyst (n=1), 
hyperpigmentation of scar (n=1), insect bite (n=1), benign cyst (n=1), and dermatofibroma (n=1). Other lesions in the 
intervention group were contact dermatitis (differential diagnosis of parapsoriasis; n=1) and unilateral naevoid 
telangiectasia (n=1).
Table 3: Lesions missed by participants and primary clinical diagnosis at clinical skin examination
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stringently for their value with regard to patient care. In 
this randomised controlled trial, we compared mobile 
teledermoscopy-enhanced skin self-examination with the 
currently recommended naked-eye skin self-examination 
for early detection of skin cancer. Although specificity 
was high at the lesion level and individual level, and 
similar between the two groups (>87%), our results did 
not support the hypothesised 20% increase in sensitivity 
to detect lesions suspicious for skin cancer, when 
participants used mobile teledermoscopy compared with 
conducting a naked-eye skin self-examination. Both the 
intervention and control groups had high sensitivity 
(≥75%) for the identification of skin cancers, but the 
mobile teledermoscopy group missed a higher number 
of skin cancers (n=17) than did the control group (n=7). 
Both groups also submitted or marked a large number of 
benign lesions on their skin, and therefore the proportion 
of relevant lesions was low in both groups. This reflects 
the fact that considering the relatively rare event of a skin 
cancer, the so-called noise-to-signal ratio is high on an 
individual person’s body, and thus considerable precision 
is required to identify suspicious skin lesions. The 
introduction of teledermoscopy into clinical practice 
could lead to a large burden for telediagnostic services if 
its use results in people submitting many benign lesions. 
However, automated algorithms excluding clearly benign 
skin lesions could reduce that burden in the near future.27
One reason for lower sensitivity in detecting skin 
cancers in the intervention group might have been their 
lower rate of conducting a whole-body skin self-
examination (70%) compared with the control group 
(84%); and lower rate of completing all three skin self-
examinations (83%) compared with the control (95%). 
We postulate that these differences could be due to the 
time needed to become familiar with teledermoscopy, or 
the effort required to image and submit each examined 
lesion via the app. More participants in the intervention 
group than in the control group reported that they asked 
Primary diagnosis 
at baseline SSE
Differential 
diagnosis at 
baseline SSE
Primary 
diagnosis at 
1-month SSE
Differential 
diagnosis at 
1-month SSE
Primary 
diagnosis at 
2-month SSE
Differential 
diagnosis at 
2-month SSE
Median (range; IQR) 6·0 (1–24; 4–8) ·· 6·0 (1–18; 4–8) ·· 6·0 (1–20; 4–8) ··
Total number of lesions 615 51 571 31 511 28
Predominantly pigmented lesions
Melanoma 0 3 (6%) 0 3 (10%) 0 2 (7%)
Naevus 395 (64%) 9 (18%) 374 (65%) 6 (19%) 340 (67%) 7 (25%)
Lentigo 49 (8%) 5 (10%) 39 (7%) 4 (13%) 34 (7%) 1 (4%)
Seborrhoeic keratosis 98 (16%) 12 (24%) 90 (16%) 7 (23%) 74 (14%) 8 (29%)
Non-pigmented lesions
Basal cell carcinoma 5 (1%) 6 (12%) 4 (1%) 1 (3%) 3 (1%) 1 (4%)
Squamous cell carcinoma 1 (<1%) 2 (4%) 0 5 (16%) 2 (<1%) 4 (14%)
Actinic keratosis 18 (3%) 6 (12%) 16 (3%) 3 (10%) 10 (2%) 3 (11%)
Angioma 12 (2%) 4 (8%) 9 (2%) 1 (3%) 11 (2%) 1 (4%)
Other* 9 (1%) 4 (8%) 7 (1%) 1 (3%) 6 (1%) 1 (4%)
Not diagnosed
No lesion found NA NA 2 (<1%) NA 8 (2%) NA
Not in focus or non-specific 28 (5%) NA 28 (5%) NA 19 (4%) NA
Excised NA NA 2 (<1%) NA 4 (1%) NA
Lesion photo monitoring
Change identified NA NA 25 (4%) NA 28 (5%) NA
No change NA NA 463 (81%) NA 435 (85%) NA
Incorrect lesion photographed NA NA 48 (8%) NA 29 (6%) NA
Excised NA NA 2 (<1%) NA 4 (1%) NA
Photographed for first time NA NA 28 (5%) NA 9 (2%) NA
Lesion image insufficient quality for 
change to be determined†
NA NA 5 (1%) NA 6 (1%) NA
Lesions not rephotographed NA NA 32 (6%) NA 26 (5%) NA
Data are n or n (%), unless otherwise specified. SSE=skin self-examination. NA=not applicable. *Includes warts, skin tags, folliculitis, erythema, focal hyperpigmentation, 
sebaceous hyperplasia, fibrous papule, excoriated bite, telangiectasia, lichen planus, benign cyst, myxoid cyst or ganglion cyst, neurofibroma, scar, bite or scratch, freckle, 
photodamaged skin, inflammatory papule, dermatitis, parapsoriasis, fibroma mucous cyst, milia, dermatofibroma, neurofibroma, atypical dermatofibroma, callus, actinic 
cheilitis, and acne. †At the 1-month SSE, 28 lesions were of insufficient quality to determine a primary telediagnosis; however, of these, 23 could still be used to determine the 
degree of change from baseline, thus only five lesions were of insufficient quality for the dermatologist to determine whether a change had occurred. At the 2-month SSE, 
19 lesions were of insufficient quality to determine a primary telediagnosis; however, of these, 13 could still be used to determine the degree of change from baseline, thus 
only six lesions were of insufficient quality for the dermatologist to determine whether a change had occurred.
Table 4: Telediagnosis of submitted lesions at baseline, 1-month, and 2-month self-skin examinations in the intervention group
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a partner to assist in checking areas of the body that are 
difficult to see, which might also have affected sensitivity. 
We did not specifically enquire whether participants 
shared the study instructions with their partners, and 
future studies should test whether training for partners 
could increase sensitivity of teledermoscopy-enhanced 
skin self-examination. In a previous study, trained 
partners became deeply engaged in checking areas of the 
body that are hard to see following skin self-examination 
training and were more likely to find concerning skin 
lesions compared with partners who had no training.28
Participants in the intervention group more commonly 
missed basal cell carcinomas (44%) than did participants 
in the control group (21%). This difference indicates that 
instructions for using mobile teledermoscopy for imaging 
basal cell carcinomas require further improvement. 
In contrast, one case of melanoma was missed by a 
participant in the control group, whereas no melanomas 
were missed by participants in the intervention group 
indicating that the provision of the asymmetry and colour 
rule via a mobile dermoscopy app was useful to guide 
intervention group participants towards photographing 
lesions suspicious of melanoma. In this study, and our 
previous studies18,19 when using mobile teledermoscopy, 
many participants had various skin conditions other than 
skin cancers that required treatment or follow-up, which 
would have remained undetected without teledermoscocpy, 
providing an additional advantage for patients of using 
this imaging technology.
In this study, up to 5% of images submitted were of 
insufficient quality for diagnosis, which is considerably 
lower than estimates from previous studies (20%),29 
indicating the imaging technology is now well advanced 
and highly usable. In most previous teledermoscopy 
studies, the imaging process was done by a health 
professional,30–32 with only few preliminary studies 
reported on images taken by the patient themselves or a 
friend or family member.17–19 Wu and colleagues and 
Manahan and colleagues reported concordance between 
the telediagnosis and in-person clinical diagnosis 
ranging from 90% to 97% when the patient photographed 
lesions with a dermatoscope.17,18 The present study found 
high management concordance of 88% between in-
person and teledermoscopy evaluation, confirming that, 
if relevant lesions are photographed by participants, they 
can be triaged by a dermatologist with high accuracy.
In addition to providing information about the value of 
mobile teledermoscopy, this study is novel in providing 
evidence from a randomised trial for the value of naked-
eye skin self-examination. The trial protocol allowed for 
stringent follow-up, requiring participants to submit 
body charts with their findings at three timepoints and 
to be seen in-person for a whole-body clinical skin 
examination. Among the control group, at the lesion 
level, sensitivity was 88% (95% CI 80–91), which is in the 
upper range of those reported by previous studies 
(25–93%),15 indicating that the participants in our study 
usually selected the correct lesions to show to a doctor, 
with even higher sensitivity at the individual level. This 
provides strong evidence for the current public health 
recommendation for skin self-examination.
This study recruited a volunteer sample who might be 
more motivated and likely to do a skin self-examination. 
Most participants were women, with a high level of 
education, and this study excluded people without an 
iPhone. Both telediagnosis and clinical diagnosis were 
done by the same dermatologist, which could have 
increased estimates of diagnostic concordance between 
telediagnosis and clinical diagnosis. We did not do a total 
body lesion count on each participant and true negative 
calculations were based on self-reported survey data 
and related clinical count data. We used face-to-face 
clinical diagnosis as the reference standard instead of 
histopathology because histopathology is not practical 
when treatments such as cryotherapy are also used.
Mobile teledermoscopy-enhanced skin self-examination 
did not result in 20% higher sensitivity than naked-eye 
skin self-examination for the early detection of skin 
cancers, thus our hypothesis was rejected. Further 
improvements to the instructions for participants on the 
relevance of non-pigmented skin lesions, training for 
partners, and the integration of automatic algorithms that 
rule out clearly benign skin lesions at the time of 
photographing might increase sensitivity of tele dermo-
scopy in the future. Naked-eye skin self-examination 
seems valuable considering the high sensitivity for sus-
pected skin cancers, and current public health recom-
mendations for regular skin self-examinations should be 
maintained.
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